Macquarie Group LTD Merus N.V. Transaction History

Macquarie Group LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $7,362 - $11,427	-395 Reduced 23.02%	1,321 $34,000
Q4 2021 Feb 11, 2022	SELL	$20.0 - $32.29 $17,380 - $28,060	-869 Reduced 33.62%	1,716 $55,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $27.23 $21,770 - $35,970	1,321 Added 104.51%	2,585 $57,000
Q2 2021 Aug 13, 2021	BUY	$20.0 - $25.48 $25,280 - $32,206	1,264 New	1,264 $27,000
Q1 2018 May 11, 2018	SELL	$16.07 - $19.87 $9,642 - $11,922	-600 Closed	0 $0

Q4 2017 Feb 15, 2018	BUY	$14.23 - $21.28 $8,538 - $12,768	600	600 $12,000

277

63.8M

1.65M

758K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $4.4B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.